Piper Sandler Initiates Coverage on MMED (NASDAQ:MMED)

Equities researchers at Piper Sandler started coverage on shares of MMED (NASDAQ:MMED) in a research note issued on Tuesday. The firm set a “neutral” rating and a $16.00 price target on the stock. Piper Sandler’s target price would indicate a potential upside of 11.50% from the company’s current price.

MMED has been the subject of several other reports. Bank of America started coverage on shares of MMED in a research report on Tuesday. They set a “buy” rating and a $27.00 price target for the company. BTIG Research assumed coverage on shares of MMED in a research report on Tuesday. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Wall Street Zen raised shares of MMED to a “hold” rating in a research report on Saturday, March 14th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.33.

MMED Price Performance

Shares of NASDAQ MMED opened at $14.35 on Tuesday. MMED has a 1-year low of $14.10 and a 1-year high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.